Tempus AI extends AstraZeneca deal with $200M commitment
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tempus AI, Inc. and AstraZeneca AB amended their Master Services Agreement, establishing a new five-year financial commitment period effective January 1, 2027, and extending the agreement through December 31, 2031. AstraZeneca committed to $200 million in fees to be paid or payable to Tempus under the MSA and other agreements between the parties and their affiliates during the renewal term. The commitment represents an annual target spend of $40 million across Tempus’s existing and future products and services, with a minimum of $32 million in fees in each calendar year.
If the $200 million aggregate commitment is not met by the end of the renewal term, the agreement extends through December 31, 2032 to address the shortfall. AstraZeneca may terminate the MSA for convenience at any time; if its financial commitments remain unfulfilled as of the effective date of termination, AstraZeneca is liable to pay Tempus the shortfall against the $200 million commitment.
8-K Event Classification
Key Figures
Key Terms
Master Services Agreement technical
Renewal Term regulatory
termination for convenience regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did AstraZeneca commit to pay Tempus AI (TEM) under the amended agreement?
What is AstraZeneca’s minimum annual commitment to Tempus AI (TEM)?
What happens if AstraZeneca does not meet its commitment to Tempus AI (TEM)?
Can AstraZeneca terminate its agreement with Tempus AI (TEM)?
AI-generated analysis. How Rhea-AI works. Not financial advice.